Services and products for preclinical and clinical research
Stem cell and drug discovery scientists around the world use our solutions to translate their research into therapies.
Service Areas
Featured Products
%20vial.jpg)
Whatʼs New
New Products for MSC Research
REPROCELL offers a variety of ready-to-ship products to support research with MSCs (also known as Mesenchymal Stem Cells, Mesenchymal Stromal Cells, or Medicinal Signaling Cells). These products include primary MSCs, iPSC-derived cell lines, media, and other culture reagents. Our cell lines are useful for differentiation and exosome production, enabling the development of diverse disease models for advanced research.
Clinical MSC Production Service
Mesenchymal Stem Cells (MSCs)—also called Mesenchymal Stromal Cells or Medicinal Signaling Cells—are involved in a variety of cell therapy and drug discovery programs. REPROCELL can help you drive your next clinical MSC project to success and ensure compliance with regulatory agencies.
Human Tissue Pharmacology
Human fresh tissue testing bridges the gap between animal studies and clinical trials. We specialize in proof of concept studies in patient-derived living tissues, increasing your clinical success rates and adding commercial value to your preclinical drug assets.
Alvetex® Bioengineered 3D Tissue Services
Complementing our fresh tissue assays by accurately recreating human biology in bioengineered tissues.
Stem Cell Services for Cell Therapy Manufacturing
GMP iPSC and MSC Master Cell Banks and cells for your cell therapy project. Compliant with regulatory standards of the FDA, EMA, and PDMA.
StemEdit™ Clinical Gene Editing Service
Achieve the genotype you need using CRISPR-SNIPER, before moving on to expensive cell bank manufacturing processes.
Global Oligonucleotide Synthesis Services
Exceptional quality oligos delivered worldwide. Custom synthesis, purification, and modification – all based on your requirements.
On the REPROCELL blog
Latest
Why mRNA Reprogramming Is the Key to Safer and Faster iPSC Generation?
Discover how mRNA reprogramming enhances the safety, efficiency, and scalability of iPSC generation for therapeutic applications. Explore REPROCELL's innovative technologies and services.
10 June 2025
New Therapeutic Targets: The Role of IL17-Related Genes in Precision Medicine
Discover how IL-17 related genes could revolutionize psoriasis treatment, offering new therapeutic targets and paving the way for precision medicine advancements.
09 June 2025
Balancing Efficacy and Cognitive Health In Bladder Assays
New approaches in OAB treatment focus on balancing efficacy and cognitive health, using alternatives to anticholinergics and personalized medicine to improve patient outcomes.
23 May 2025
Breaking Barriers in Women’s Health: The World’s First Live Birth Using Fertilo
Discover how Gameto achieved the world’s first live birth using Fertilo, a revolutionary in vitro oocyte maturation technology. Learn about its stem cell-driven innovation and how it's transforming fertility care for women worldwide.
21 May 2025
Key Strategies Central Labs Use to Fast-Track Time to Market
Learn how central labs use automation, outsourcing, and AI to accelerate drug development, reduce costs, and improve clinical trial accuracy and efficiency.
21 May 2025
Upcoming Events
Conferences we will be attending, and webinars hosted by us
Corporate News
REPROCELL Launches Immune Modulated iPSC Products
REPROCELL USA unveils GMP manufacturing facility for hiPSC and hMSC, revolutionizing stem cell therapy with closed-system technology.
05 May 2025
REPROCELL Inc. today announced that its partner, Steminent Biotherapeutics Inc., reported positive results on April 24, 2025, from Phase II clinical trials conducted in Taiwan and Japan for the stem cell therapy "Stemchymal®". REPROCELL holds the exclusive commercialization license agreement for Stemchymal in Japan for the treatment of Spinocerebellar Ataxia (SCA).
25 April 2025
Gameto Announces FDA IND Clearance for Fertilo utilizing REPROCELL’s StemRNA™ Clinical Seed iPSCs
Gameto's FDA IND clearance for Fertilo marks a milestone as the first iPSC-based therapy enters U.S. Phase 3 trials, leveraging REPROCELL’s StemRNA™ Clinical Seed iPSCs.
06 February 2025